Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease

Figure 1 Interplay between coronavirus disease 2019 and metabolic-associated fatty liver disease. COVID-19: Coronavirus disease 2019; MAFLD: Metabolic-associated fatty liver disease; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2.

Figure 2 Selection of coronavirus disease 2019 therapy in metabolic-associated fatty liver disease patient. ¹High risk of progression - advanced age ≥ 65-yr-old, immunocompromised state or multiple medical co-morbidities. Hypoxemia: SpO₂ ≤ 94% on room air; ECMO: Extracorporeal membrane oxygenation; Mild disease: Cough, upper respiratory tract symptom and absence of dyspnea; Severe: Hypoxemia or need for supplemental oxygen; Moderate: Dyspneic patient and absence of severe disease features. ALT: Alanine transaminase; AST: Aspartate transaminase; COVID: Coronavirus disease; CTP: Child Pugh score; LFT: Liver function test; ULN: Upper limit of normal.